Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company ...

Black men who were identified as sexual minorities were more receptive to long-acting injectable pre-exposure prophylaxis ...

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...

Approval of first twice-yearly HIV pre-exposure prophylaxis was based on results from the Phase III PURPOSE 1 and PURPOSE 2 trials, which show that ≥99.9% of patients treated with Yeztugo remained HIV ...

Increased PrEP usage is linked to decreased HIV diagnosis rates, with a notable decline from 13.0 to 10.6 per 100,000 over a decade. State-level PrEP coverage significantly impacts HIV diagnosis rates ...

The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts believe this twice a year treatment could be a game changer in the fight ...

Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say ...

The challengers argued that members of the Preventive Services Task Force were improperly appointed because they were not ...

Planned Parenthood of the Pacific Southwest has started offering an HIV prevention injection as part of its services, it was ...

"Analysis shows Yeztugo approval a ‘momentous step’ for HIV prevention" was originally created and published by ...